Going-concern and financing risk
The company has recurring losses and no product sales, so it must raise capital to continue operations.
- Scope
- Equity offerings, ATM, ELOC, debt, and collaborations
- Materiality
- high
Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company developing gene-based treatments for cancer and diabetes. Its oncology programs use the ONCOPREX delivery system to deliver tumor suppressor genes, while its diabetes work centers on adeno-associated virus-based gene therapy licensed from the University of Pittsburgh.
3.84
3.84
| % | |
|---|---|
| Oncology gene therapy platform | 0% Systemic, non-viral gene therapy candidates and delivery technology for cancer. |
| Diabetes gene therapy platform | 0% Licensed gene therapy programs targeting Type 1 and Type 2 diabetes. |
| Clinical development programs | 0% Human trials and related regulatory work for lead oncology candidates. |
| Preclinical research | 0% Animal-model and IND-enabling studies supporting future product candidates. |
| Licensed technology and know-how | 0% Exclusive and non-exclusive rights from the University of Pittsburgh. |
Genprex does not currently sell commercial products; its near-term counterparties are research institutions, clinical...
- Research collaboratorsprimary
Universities and scientific partners that perform animal-model and translational studies to advance the pipeline.
- Clinical trial participants and sitesprimary
Patients and trial centers enrolled in Acclaim-1 and Acclaim-3 to generate efficacy and safety data.
- Regulatory authoritiesprimary
FDA and other agencies that must clear IND-enabling work and approve clinical advancement.
- Manufacturing and development vendorssecondary
Specialized third parties that support process scale-up, formulation, and clinical supply.
- Future commercial patientsemerging
Cancer and diabetes patients who would be treated if the company reaches approval and launch.
Genprex is headquartered in the United States and its development work is centered there, including clinical...
- •United States is the core operating base and clinical-development center
- •FDA interactions are central because U.S. approval is the main near-term gate
- •Europe is a stated regulatory target for future product approval
- •Worldwide license rights expand the potential commercial footprint
- •No country revenue disclosed because the company has not generated product sales
Genprex is prioritizing advancement of its lead oncology trials while continuing preclinical and IND-enabling work for...
01
Complete enrollment and advance lead oncology trialsshort-term
Clinical data are the main value driver and are needed for regulatory and partnering optionality.
02
Advance diabetes program toward IND-enabling workmedium-term
The diabetes platform broadens the pipeline and could create a second development path.
03
Preserve liquidity through cost reduction and financingshort-term
The company has no product revenue and depends on external capital to fund R&D.
04
Optimize manufacturing and development executionmedium-term
Gene therapy programs require reliable, scalable manufacturing to support trials and future launch.
Genprex is a pre-revenue biotech company with substantial clinical, regulatory, and financing risk...
Clinical trial failure
Lead programs are still in development and may not demonstrate sufficient efficacy or safety.
- Scope
- Acclaim-1, Acclaim-3, diabetes preclinical work
- Materiality
- high
Regulatory approval risk
FDA and other regulators may require additional studies or reject applications.
- Scope
- IND-enabling studies, U.S. and Europe approvals
- Materiality
- high
Nasdaq delisting risk
Failure to meet continued listing standards could impair liquidity and financing access.
- Scope
- Minimum bid price and stockholders' equity requirements
- Materiality
- medium
Manufacturing and scale-up risk
Gene therapy production is complex and vendor transitions can affect quality and timing.
- Scope
- New manufacturing vendors and process adaptation
- Materiality
- medium
Research and development costs
Clinical, preclinical, and manufacturing costs flow through earnings immediately
Going-concern assessment
Material disclosure affecting investor assessment of solvency
Equity financing and dilution
Common stock outstanding and capital structure
Accruals and vendor-related estimates
Expense timing and liabilities
: 28.4.2026